MUSTAFA MERTER - Academia.edu (original) (raw)

Papers by MUSTAFA MERTER

The Egyptian Journal of Haematology

Meme sağlığı dergisi, 2012

$Research paper thumbnail of A remarkably long remission achieved with ibrutinib monotherapy in a patient who was diagnosed with steroid refractory sclerosing chronic GVHD$

$Research paper thumbnail of Ibrutinib as a monotherapy for relapsed or refractory DLBCL patients: a single-center experience$

Leukemia Research, 2019

inflammatory disease and/or regular antiaggregant, anticoagulant, antiinflammatory drug use and w... more inflammatory disease and/or regular antiaggregant, anticoagulant, antiinflammatory drug use and who were lost to follow-up. 25 DLBCL patients (13 females/12 males) were qualified for the study. Hemogram, biochemistry parameters and maximum SUV max values in Positron Emission Tomography (PET-CT) and overall survival (OS) and progression free survival (PFS) values of the patients were retrospectively collected. Results: The mean age of the patients was 48.68±12.9 years. The mean OS was 37.96±5.74 months, the mean PFS was 34.4±5.70 months and the mean SUVmax was 19.66±9.51 months. Pre-treatment platelet distribution width (PDW) (16.6±3.77 fl) was significantly lower than post-treatment PDW (18.26±3.67 fl) (p = 0.003). Pre-treatment neutrophil lymphocyte ratio (NLR) (7.88±2.09 fl) was significantly higher than post-treatment NLR (2.80±1.82 fl) (p=0.023). There was a positive correlation between pretreatment LDH level and pre-treatment platelet level (r=0.50, p=0.01). While there was a negative correlation between MPV and PDW before treatment (r=-0.46, p=0.02), there was a strongly positive correlation with OS and PFS (r=0.83, p<0.001, r=0.79, p<0.001, respectively). While there was a strongly negative correlation between pre-treatment PDW and OS and PFS (r=-0.79, p<0.001, r=-0.81, p<0.001, respectively), there was a negative correlation between post-treatment PDW and OS and PFS (r=-0.53, p=0.01; r=-0.50, p=0.014, respectively). Conclusion: In this study, we found that a high MPV and low PDW prior to chemotherapy was associated with increased OS and PFS in patients with DLBCL, which supports the findings of previous studies. Platelets are playing an important role in tumor-associated inflammatory response and cancer progression. Although the number of studies is limited, recent studies showed the negative effect of a low MPV on different types of lymphoma. More investigations with larger sample size are needed to explain the underlying mechanisms about the influence of platelets on the prognosis of DLBCL patients.

Biology of Blood and Marrow Transplantation, 2012

demonstrated a partial response at the time of transplant. The conditioning was tolerated well wi... more demonstrated a partial response at the time of transplant. The conditioning was tolerated well with no treatment related mortality (TRM) within 100 days and no grade 4 toxicities. All pts developed grade 1-3 mucositis, while 13 reported diarrhea (7 pts grade 3) and 21 developed liver toxicity (transaminitis and/or bilirubin elevation); 2 pts with grade 3. Four pts had grade 3 lung toxicities and 1 pt grade 3 colitis. All pts engrafted: ANC .500 achieved on day 8-17 (median 10); platelets .25,000 on day 11-58 (median 18); platelets .50,000 on day 14-119 (median 23). Overall 1-yr survival is 95% (1 pt died 306 days post transplant); 3 year survival is 72%. All deaths were related to a disease recurrence: two pts with Ewing sarcoma, 2 with rhabdomyosarcoma, and one each with neuroblastoma, Wilms and medullodlastoma. These data suggest that the B-M-T preparative regimen followed by an ASCT was tolerated well without unexpected or severe toxicities; pts had prompt engraftment and 0% TRM. The survival data are encouraging compared to historical data. This novel conditioning regimen with a favorable toxicity profile can be used in the future as a platform for gene therapy, immunebased cellular therapies or to intensify local control with prompt administration of intensity modulated radiation therapy (IMRT) such as helical-tomotherapy.

Amaç: Bu çalışmada, kemik iliğindeki (Kİ) blast oranı >%30 olan olguları da içeren akut miyelo... more Amaç: Bu çalışmada, kemik iliğindeki (Kİ) blast oranı >%30 olan olguları da içeren akut miyeloid lösemili (AML) yaşlı hastalarda, azasitidinin (AZA) etkinliğinin ve güvenliğinin araştırılmasını amaçladık. Gereç ve Yöntemler: Bu geriye dönük, çok merkezli çalışmaya, yoğun kemoterapi için uygun olmayan ya da konvansiyonel tedavilere rağmen hastalığı ilerleyen >=60 yaştaki 130 hasta dahil edildi. Bulgular: Ortanca yaş 73 idi, hastaların %61,5'inde Kİ blast oranı >%30 olarak bulundu. Hastalar, ortanca 4 döngü (1-21 aralığında) AZA almıştı. Başlangıç genel yanıt oranı [tam yanıtı (TY)/eksik düzelmenin olduğu TY/kısmi yanıtı içeren] %36,2 idi. Herhangi bir hematolojik düzelme (HD), tüm hastaların %36,2'sinde tespit edildi. HD tedaviye yanıtsız hastaların %27,1'inde de saptandı. Ortanca genel sağkalım, yanıt verenlerde 18 ay, yanıt vermeyenlerde 12 ay idi (p=0,005). Tedaviye yanıtsız hasta grubunda HD'nin, HD olmayanlara kıyasla genel sağkalımı arttırdığı görüldü (...

Bone Marrow Transplantation, 2016

Hematology, Transfusion and Cell Therapy, 2020

hematol transfus cell ther. 2 0 2 0;4 2(S 1):S35-S78 S65 therefore male stromal structure was ter... more hematol transfus cell ther. 2 0 2 0;4 2(S 1):S35-S78 S65 therefore male stromal structure was terminated with >12 g/dL Hb values at 12 months, the mean value in female recipients was <12 g/dL. Male allogeneic HSCT recipients are more fortunate than women in this respect but in the study, no significant difference was found between women who have male donors and gender-matched sex in hemoglobin elevation. Conclusion: In our study, no significant difference was found between women who have male donors and gendermatched sex in hemoglobin elevation. Finally, we think that in patients with both male and female donors, it can be concluded that the recipient's hemoglobin value may be higher by choosing a male donor.

Ileri evre pankreas kanserli hastalar kotu bir prognoza sahiptir ve tedavileri medikal onkoloji p... more Ileri evre pankreas kanserli hastalar kotu bir prognoza sahiptir ve tedavileri medikal onkoloji pratiginde onemli bir problem olmaya devam etmektedir. Bu nedenle bu calismada metastatik veya lokal ileri pankreas kanseri tanisiyla tedavi edilen hastalarimizin klinik ozelliklerini ve tedavi sonuclarini retrospektif olarak degerlendirmeyi amacladik. Bu calisma icin, Ocak 1995-Mayis 2012 tarihleri arasinda tedavi edilen ve klinik bilgileri elde edilebilen toplam 183 olgunun dosyasini retrospektif olarak inceledik. Hastalarin demografik ozelliklerini, almis olduklari tedavileri ve sagkalim sonuclarini belirledik. Olgularin 123'u erkek, 60'i kadin olup ortanca yas 60 (33-84) idi. Tani aninda 105 olgu metastatikti ve en sik metastaz yeri karacigerdi. Yetmis bes hasta gemsitabin + 5-Fluorourasil, 42 hasta gemsitabin, 24 hasta gemsita-bin+sisplatin ve 3 hasta UFT+sisplatin ile tedavi edilmisti. Kemoterapi ile olgularin %6'sinda tam yanit, %8.7'de kismi yanit ve %9.8'de st...

Transfusion and Apheresis Science

Ultrasound Quarterly

Objective Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferativ... more Objective Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative diseases that can transform to secondary myelofibrosis (SMF). In this study, we evaluated spleen stiffness using shear-wave elastography (SWE) as a predictor of progression to SMF. Methods Participants were grouped as healthy volunteers (HVs), PV/ET patients, and SMF patients. Participants' spleen sizes, spleen stiffness values, bone marrow fibrosis degrees, and the other parameters were evaluated. Spleen stiffness values and spleen sizes were compared between groups. Results Of the 121 participants included in this study, 52 patients were HVs, 52 patients were PV and/or ET patients, and 17 patients were SMF patients. In terms of age and sex, there was no difference between groups. Splenic parenchymal stiffness median values by using SWE were found to be 0.82 m/s in HVs, 1.41 m/s in PV/ET patients, and 2.32 m/s in SMF patients (P < 0.001). In terms of median length of the spleen, the difference between groups was significant (P < 0.001). In addition, we found a significant positive correlation between spleen stiffness and bone marrow fibrosis degree (P < 0.001, r = 0.757). However, in multivariate analysis, there was no strong independent risk factor for spleen stiffness. Conclusion In this study, we showed that measurement of spleen stiffness using SWE can distinguish SMF from PV/ET patients and HVs. Therefore, we believe that SWE may be used as a noninvasive and easily accessible method to check the fibrotic progression of bone marrow in PV and ET patients to monitor the transformation to SMF, and enables to detect fibrosis in early phase.

$Research paper thumbnail of Lenalidomide treatment in relapsed/refractory B-cell lymphomas: A single center real-life experience$

Medicine Science | International Medical Journal, 2022

Blood, 2021

Introduction: To investigate the demographics and treatment details of the myeloma patients who w... more Introduction: To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods: Patients who were recorded on the database of Turkish Myeloma Registry project were included in this study if they had only received one or two lines of therapy. Demographics, patient, and disease related parameters both at the time of diagnosis and at the follow up and treatment outcomes were presented. Results: A total of 532 patients were included in the study, and 44% of the patients were female. Median age at the time of diagnosis was 63 (30-106). 47.7% of the patients were diagnosed with IgG myeloma. According to the ISS risk stratification, 20.4% of patients had ISS 1, 34.7% of patients had ISS 2 and remaining 44.9% had ISS 3 disease. Defining high risk disease as harboring one or more of these following cytogenetic abnormalities; del 17p, t(4;14), t(14;16) or t(14;20); 7.1% of the patients w...

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2021

BACKGROUND AND OBJECTIVES Stem cell transplantation is a growing treatment strategy for most mali... more BACKGROUND AND OBJECTIVES Stem cell transplantation is a growing treatment strategy for most malignant and non- malignant hematological diseases. Plerixafor and granulocyte colony stimulating factor (G-CSF) are usually used in mobilization regimens to increase the CD34+ cell count in the harvest. Heparin is a sulphated glycosaminoglycated polymer with 12-15 kDa mass. Heparin inhibits the CXCR4/SDF1 axis, as does plerixafor. In this study, our aim was to investigate the effect of using heparin on stem cell mobilization and harvesting. MATERIALS AND METHODS We administered 5000 units of unfractioned heparin intravenously in 150 mL (mL) of isotonic sodium chloride solution, 15 min before the stem cell harvesting procedure to 141 patients who underwent bone marrow transplantation between the years of 2018 and 2019 at our Stem Cell Transplantation Unit. Thirty patients were included as a control group, and they were not given heparin. The study population included patients with multiple ...

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2021

PURPOSE Pralatrexate is a new generation antifolate treatment agent used for the treatment of rel... more PURPOSE Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turkey, contributing to the literature on the effectiveness of pralatrexate therapy in peripheral T-cell lymphomas by determining the response levels of such patients to the therapy. The study also attempts to clinically examine the major side effects observed in patients during treatment with pralatrexate. METHODS The study included patients with peripheral T-cell lymphoma followed up in the hematology units of several hospitals in Turkey. Overall, 20 patients aged 18 and over were included in the study. RESULTS The median age at the time of diagnosis was 58.5 years. PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) subtype was in 40% of patients, making the PTCL-NOS the most common subtype in the study. In general, most...